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While on the one hand causing damage to the gastrointestinal
mucosa (Hawkey, 1996), aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) also have some potentially anti-
carcinogenic activity. These include repression of prostaglandin
synthesis through inhibition of cyclooxygenase (COX) (Marnett,
1992; Lupulescu, 1996), induction of apoptosis (Shiff and Rigas,
1997) and inhibition of angiogenesis (Jones et al, 1999). Indeed,
COX inhibitors have been reported to suppress growth of gastric
cancer in a human gastric cancer cell line (MKN45) (Tsuji et al,
1996; Sawaoka et al, 1998c) and in gastric cancer xenografts trans-
planted into nude mice (Sawaoka et al, 1998b). Accumulating
evidence of a clinically significant anticarcinogenic effect of
aspirin has so far mainly pertained to colorectal cancer (Kune et al,
1988; Rosenberg et al, 1991; Giardiello et al, 1993; Thun et al,
1993; Schreinemachers and Everson, 1994), while data from the
combined epidemiologic literature regarding gastric cancer and
aspirin are less convincing (Isomaki et al, 1978; Gridley et al,
1993; Thun et al, 1993; Schreinemachers and Everson, 1994).
Recently, 2 case–control studies indicated that the risk for stomach
cancer is reduced in users of NSAIDs (Farrow et al, 1998; Zaridze
et al, 1999). 
Using data from a large population-based case–control study
primarily concerned with diet and other life-style factors (Ekstrom
et al, 2000), we aimed to further explore the possible protective
effect of aspirin on gastric cancer. Available data enabled us to
study this association for each tumour site (cardia/non-cardia) and
histological subtype separately, while taking other risk factors,
including  H. pylori, into account. 
METHODS 
Study methods have been described in detail elsewhere (Ekstrom
et al, 1999a). Briefly, the study base consisted of all native Swedes
aged 40–79 years, living in 5 Swedish counties (population 1.3
million) at any time from February 1989 to January 1995. All
gastric adenocarcinomas in the study base were eligible as cases. 
Study participants 
A comprehensive scheme for case ascertainment, with contact
persons at all hospitals, continuous surveillance at all pathology
departments, and a final check at the regional cancer registers up
to 30 months after the end of the study period, exceeded that of the
Swedish Cancer Register (Ekstrom et al, 1999b). Of the 908
patients who met the eligibility criteria, 567 (62%) agreed to
participate in a face-to-face interview. The reasons for non-
participation were early death or terminal illness in 270 (29.7%),
mental or physical illness other than gastric cancer in 40 (4.4%),
patient refusal in 28 (3.1%), while 3 (0.3%) could not be located. 
Tumour subsite and histologic type [according to Laurén
(1965)] were determined using standardized reports from the clin-
icians, supplemented by data from the patient records. All histo-
logical slides were re-evaluated by one pathologist. Cancer of the
gastric cardia (n = 90) was defined as an adenocarcinoma with its
centre located within one centimetre proximal and 2 centimetres
distal to the gastro-oesophageal junction (Misumi et al, 1989).
Tumours were classified according to their predominant histologic
pattern as being of intestinal (n = 337), diffuse (n = 184), or mixed
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origin or the histologic type in 0.9% and 1.6%, respectively. 
The control subjects were randomly selected from a continu-
ously updated population registry covering the entire study base.
We frequency-matched the controls to mimic the age and gender
distribution of cases. Of the 1534 contacted control subjects, 1165
were interviewed (76.0%). The reasons for non-participation were
refusal in 245 (16.0%), mental or physical illness in 90 (5.9%),
while 34 (2.2%) could not be located for interview. 
Exposure data 
We obtained information through face-to-face interviews
conducted by specially trained professional interviewers
employed by Statistics Sweden. Concealment of case/control
status was impossible, but the interviewers were instructed to
treat cases and controls in a strictly uniform way. The inter-
viewers were, furthermore, unaware of the study hypothesis.
Questions were asked about use of pain relievers earlier than 
2 years before the interview and the participants were prompted
to give specific brand names. The subjects reported the frequency
of pain reliever use per month and, when taking them, the number
of tablets used per day. We defined ever users of aspirin as those
who reported ever use of pain relievers containing salicylic acid
with a frequency equal to or exceeding one tablet per month. Ever
use of non-aspirin and other pain relievers was defined corre-
spondingly. To obtain a measure of monthly dose, we multiplied
(tablets per day) ´ (number of days using pain relievers per
month). The distribution was skewed towards low intake, and to
attain categories of reasonable size, while at the same time being
able to examine a group that was significantly exposed, the
monthly dose variable was transformed into categories of <1,
1–29, and ³ 30. The median value in each category was 0.5, 2,
and 60 tablets per month, respectively, and the highest category
represented the 90th percentile of exposure. 
During the last years of our study, we collected serum samples
for the study subjects (297 cases and 245 controls). Serum IgG
antibodies to H. pylori were determined using an enzyme-linked
immunosorbent assay (HM Cap®) with a reported sensitivity and
specificity of 94–98% (Graham and Evans 1994) and 92–97%
(Marchildon et al, 1996), respectively. 
For the multivariate analyses, we considered as covariates a
weighted life-time average of socio-economic status divided into 
5 categories (Hansson et al, 1994), smoking habits (non-smoker,
cigarette smoker for <30 years, cigarette smoker for ³30 years), 
H. pylori serostatus (positive vs. negative), intake of fruit and
vegetables (above or below the median among controls) and upper
gastrointestinal symptom history (negative vs. positive defined as
ever-use of H2-receptor antagonists or physician-diagnosed peptic
or gastric ulcers). 
Statistical methods 
We computed odds ratios (OR) and 95% confidence intervals (CI)
by using unconditional logistic regression. Model parameters were
estimated by the maximum likelihood method (Hosmer and
Lemeshow, 1989). All main effect models included the frequency
matching factors age and gender. We tested for linear trend by
constructing ordinal variables through assigning consecutive inte-
gers to consecutive levels of the categorized variables (Wald’s
test). Two-sided P values were used in all analyses. 
RESULTS 
We excluded 37 cases and 25 controls because they reported a
previous subtotal gastrectomy. Relevant data on use of pain
relievers was missing or incomplete for 50 cases and 85 controls.
For 71 cases and 137 controls that reported multiple drug use, we
did not obtain data on drug-specific doses. Therefore, some
analyses (including those evaluating possible dose effects) were
restricted to individuals for which this information was available. 
Selected characteristics of case and control subjects are
presented in Table 1. The male/female ratio was 2:1. Mean age for
cases and controls was 67.8 and 66.9 years, respectively. The
corresponding data for the group tested for H. pylori status was
68.2 and 67.1 years. 
Table 2 presents unconditional logistic regression-derived odds
ratios for the association between use of aspirin and gastric cancer
risk. We observed a moderately strong inverse association between
aspirin use and gastric cancer, indicating a 20–30% lower risk
among aspirin users. The risk deficit was less convincing for non-
cardia cancer of the diffuse type. Gastric cancer risk fell with
increasing frequency of aspirin use (P for trend = 0.02), and those
who used at least 30 tablets per month or more had a 40% (ns)
lower risk than those who used less than 1 tablet per month (Table 3).
Use of non-aspirin NSAIDs was not associated with a lower 
risk of gastric cancer (OR = 1.1, 95% CI = 0.6–1.4), although the
small number of exposed individuals (27 cases and 54 controls)
made the estimate unstable. We further explored use of other pain
relievers (paracetamol and dextropropoxifen) and found no associ-
ation with gastric cancer risk (data not shown). 
Adjusting for socioeconomic status, cigarette smoking, upper
gastrointestinal symptoms and intake of fruit and vegetables did
not change our results materially, nor did controlling for H. pylori
infection within the group for which data on H. pylori status was
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Table 1 Characteristics of 567 cases of gastric cancer and 1165 control
subjects generated in a population of 5 countries in Sweden 
Cases (%) Controls (%) 
Age 
40–59 103 (19) 201 (18) 
60–69 155 (29) 363 (32) 
70–79 272 (51) 576 (50) 
Gender 
Female 185 (35) 381 (33) 
Male 345 (65) 759 (67) 
Cigarette smokingb
Non-smokers 255 (48) 592 (52) 
<30 yearsa 108 (20) 275 (24) 
³30 years 167 (32) 269 (24) 
Socioeconomic statusb
Unskilled manual workers 259 (49) 441 (39) 
Skilled manual workers 124 (23) 260 (23) 
Non-manual workers 90 (17) 295 (26) 
Self-employed ³19 years 23 (4) 54 (5) 
Farmers ³19 years 33 (6) 89 (8) 
Helicobacter pylori infectionc
No 80 (28) 107 (45) 
Yes 201 (72) 132 (55) 
a Median duration of cigarette smoking among controls who were smokers. 
b Non-additivity due to missing data on smoking (n = 4) and socioeconomic
status (n = 2). c H. pylori serology was assessed for a subset of the
population (n = 520). available. Use of aspirin was similar for subjects with and without
reported upper gastrointestinal tract symptoms (61% and 60% for
those with and without physician-diagnosed peptic or duodenal
ulcers, respectively, and 58% and 60% for users and non-users of
H2-blockers, respectively). 
Among the subjects who were tested for H. pylori serology, we
performed a stratified analysis according to serostatus. Although
hampered by small numbers, this analysis revealed a non-
significant tendency for effect modification. Among the H. pylori-
positive subjects the risk was reduced by 40%, whereas the risk
reduction among the H. pylori-negative subjects was only 20%
and statistically non-significant. The difference in risk between 
H. pylori strata was, however, not statistically significant, nor was
the interaction term in our full logistic regression model. 
DISCUSSION 
In this large population-based case-control study, we found a
moderately strong inverse and apparently dose-dependent associ-
ation, although only of borderline statistical significance, between
use of aspirin and gastric cancer risk. This inverse association was
apparent for both cardia and non-cardia cancer, but uncertain for
non-cardia cancer of the diffuse type. 
A few cohort studies have investigated the relation between use
of NSAIDs and gastric cancer risk. Some of these studies found a
negative association (Gridley et al, 1993; Thun et al, 1993), while
others did not (Isomaki et al, 1978; Schreinemachers and Everson,
1994). Results from an American population-based case–control
study showed odds ratios of 0.55 for stomach adenocarcinomas
and 0.88 (not statistically significant) for gastric cardia adenocar-
cinoma among regular users of aspirin, compared to never-users
(Farrow et al, 1998). With the same exposure categories, a
hospital-based case–control study from Moscow reported odds
ratios of 0.49 and 1.14 (not statistically significant) for non-cardia
and cardia cancer, respectively (Zaridze et al, 1999). Our findings
largely confirm the results of these 2 case–control studies,
although they differ with respect to the association between aspirin
and cardia cancer. Despite different epidemiologic patterns for
cardia and non-cardia cancer (Morales, 1997), we find it plausible
that a protective effect of aspirin, mediated through its anti-
inflammatory properties, would pertain to both tumour sites. 
Some weaknesses of our study should be noticed. The low
participation rate among our cases might have introduced bias, but
would explain our results only if non-participation was strongly
linked to high aspirin consumption. Since non-participation among
cases was typically due to late notification to the study secretariat
by the clinicians, it is unlikely that non-participating cases differed
importantly from participating ones with respect to drug consump-
tion habits. An important reason for the low participation rate in
comparison with other studies is our thorough case ascertainment,
which inflated the denominator. The analyses excluding subjects
for whom drug-specific dosage information was not available
showed somewhat stronger associations than the analyses
including these individuals. Because of the questionnaire design,
these individuals were those who reported use of more than one
type of pain reliever. The observed difference may be due to a
greater non-differential misclassification among multiple drug
users, but the possibility of counteracting effects of other types of
pain relievers or chance fluctuations cannot be excluded. 
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Table 3 Odds ratios (ORs)a and 95% confidence intervals (CIs) for use of
aspirin in relation to gastric cancer 
Controls Cases 
(n = 409)d (n = 918)d ORa
Number of tablets per monthb
<1 306 624 1.0 (ref.) 
1–29 89 247 0.8 (0.6–1.0) 
³30c 14 47 0.6 (0.3–1.1) 
P (trend) 0.02 
aAdjusted for age, gender and socioeconomic status. bDaily dose multiplied
by frequency of use per month. c90th percentile of the exposed subjects.
dMissing information on use of pain relievers (n = 135) and drug-specific
doses (n = 208). 
Table 4 Distribution of cases with gastric cancer and controls by
Helicobacter pylori by status and aspirin use 
Aspirin useb
Group No Yes 
Helicobacter pylori positive cases 124 65 
controls 68 53 
ORa (95% CI) 1.0 (ref.) 0.6 (0.4–1.0) 
Helicobacter pylori negative cases 45 22 
controls 58 38 
ORa (95% CI) 1.0 (ref.) 0.8 (0.4–1.5) 
aAdjusted for age, gender and socioeconomic status. bDefined as equal to or
exceeding one tablet per month.
Table 2 Odds ratios (ORs)a and 95% confidence intervals (CIs) for use of aspirin in relation to gastric cancer, by site and histologic subtype
Non-Cardia
All gastric cancer   Cardia Non-Cardia Intestinal Diffuse 
Controls Cases OR (95% CI) Cases OR (95% CI) Cases OR (95% CI) Cases OR (95% CI) Cases OR (95% CI) 
Use of asprinb
No 624 306 (Ref.) 53 (Ref.) 249 (Ref.) 141 (Ref.) 85 (Ref.) 
Yes 294 103 0.7 (0.6–1.0) 15  0.6 (0.3–1.1) 88 0.8 (0.6–1.0)  48 0.8 (0.5–1.1) 32 0.9 (0.6–1.3) 
Use of aspirinb,c
No 631 310 (Ref.) 53 (Ref.) 253 (Ref.) 143 (Ref.) 86 (Ref.) 
Yes 424 170 0.8 (0.7–1.1) 25  0.7 (0.4–1.2) 145 0.9 (0.7–1.1)  74 0.8 (0.6–1.1) 62 1.1 (0.8–1.5) 
aAdjusted for age, gender and socioeconomic status. bDefined as equal to or exceeding one tablet per month. cIncluding subjects with missing specific dosage
information (n = 208). All information on use of pain relievers was missing for 135 individuals. An undiagnosed gastric cancer with early symptoms may have
altered the use of pain relievers and thus contributed to our
finding. To reduce the risk of such reverse causation, our questions
regarding use of pain relievers specifically inquired about use
earlier than 2 years before the interview. Furthermore, we asked
about ulcer history and use of H2-receptor antagonists as surrogate
variables for upper gastrointestinal symptoms that may have
caused a discontinued intake of pain relievers. We did not,
however, find differences in aspirin use among those with symp-
toms as compared to those without. Recall bias is unlikely since
the public is unaware of the study hypothesis, and since it is
improbable that such bias would vary across histological strata.
Non-differential misclassification of exposure may have been
considerable but should, however, only underestimate the
observed association (Rothman, 1986). 
Consistent with earlier published data we observed, although
with limited precision, that the inverse association between gastric
cancer and aspirin appeared somewhat stronger for individuals
infected with H. pylori (Zaridze et al, 1999). Effect modification
by H. pylori suggests that one of the mechanisms by which aspirin
confers protection may be directly or indirectly linked to H. pylori-
associated carcinogenesis or related to factors conducive to 
H. pylori colonization. The protective effect of aspirin may be
neutralizing the up-regulated COX-2 activity that has been associ-
ated with H. pylori infection (Sawaoka et al, 1998a). 
In summary, the results of this population-based case–control
study provides further support for the hypothesis that use of
aspirin reduces the risk of gastric cancer, but the putative 
protection appeared to be less dramatic than in some recent
reports. 
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